These are the first results for any COVID-19 vaccine in children under the age of 12. The companies plan to submit the data to the U.S. Food and Drug Administration for an emergency use authorization.

Approximately 2,270 children were administered a two-dose regimen of 10 µg. By comparison, people 12 and older received two doses of 30 µg three weeks apart. The subjects' SARS-CoV-2-neutralizing antibody geometric mean titer was 1,197.6 (95% confidence interval, 1106.1-1296.6), demonstrating a strong immune response in children one month after the second dose.

Results of the vaccine's efficacy in children younger than 5 should be available soon.

FDA authorizes 3rd COVID vaccine dose for immunocompromised individuals
The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations for both the Pfizer-BioNTech and Moderna COVID-19 vaccines.

Africa to get doses of Pfizer-BioNTech COVID-19 vaccine
Pfizer and BioNTech have signed a letter of intent with South Africa-based Biovac Institute to manufacture and distribute the companies' COVID-19 vaccine...

U.S. to donate 500M doses of Pfizer-BioNTech COVID-19 vaccines
The U.S. government is buying 500 million doses of the Pfizer-BioNTech COVID-19 vaccine to distribute to low- and lower middle-income countries and...

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents...

Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration for approval...